Immunotherapeutic Strategies in Solid Tumor: Current Status and Emerging Trends
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (31 March 2019)
Special Issue Editor
Special Issue Information
Dear Colleagues,
The recent impact of immunotherapeutic agents has firmly established the ability and importance of the immune system in fighting various malignancies. However, responses to immunotherapy varies across tumor types and relates to the heterogeneity of both tumors and individual patients. Here, we discuss how tumor-intrinsic cues, genetic and epigenetic processes, environmental metabolites, and host-derived immune cells might impact the efficacy and resistance often seen during immune checkpoint blockade treatment.
This Special Issue will focus on emerging trends in both tumors known to be sensitive and resistant to immunotherapy agents, touching on elements of immune suppression, immune stimulation, the immune microenvironment, and novel combinatory approaches to enhance immunotherapies. Topics include, but are not limited to:
Immune checkpoint inhibitors
Immune suppression
- by the tumor microenvironment
- by tumor-release factors
- in peripheral compartments
- regulatory T cells
- MDSCs
Inflammation
Oncolytic viral therapy
Resistance to immunotherapy
Vaccines
- DC-based
- proteins
- nucleic acids
- cellular
- nanomaterials
Immune transfer
- adoptive T cells
- CAR-T cells
- serologic
- antibodies and constructs
Combination therapies
Dr. Devalingam Mahalingam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel therapeutics
- early phase clinical studies
- immunotherapy and cancer biology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
